- Cardiovascular Research Team, San Carlo Clinic, Milan, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, ItalyInterests: Percutaneous tricuspid interventions; Conduction disturbances after TAVI; Antithrombotic therapy in TAVI patients; Percutaneous treatment of bicuspid valve
Interventional cardiology is evolving rapidly with an increased need for better results in treatment of coronary artery disease (CAD) which is the leading cause of death worldwide.
The introduction of drug eluting stents (DES) revolutionized treatment of coronary artery disease by reducing the rate of restenosis to 5%-10%. However, the use of DES in complex patients such as diabetic, small vessel disease, long lesions and coronary artery bypass grafting is still associated with higher risk of ISR.
In recent years, drug-coated balloons (DCB) have emerged as a potential alternative to combat restenosis and fulfill the goal of the DES without duplicating the limitations encountered with previously available devices. With currently available paclitaxel and sirolimus balloon coatings DCBs are showing non-inferiority vs DES in different patient settings. However, a major challenge in the management of coronary artery disease is the accurate identification of those patients who will benefit from either DCB or DES and which coating outperforms the other at long term.
CAD has an increasing incidence, prevalence and mortality rate. In light of recent advances in various delivering and coating devices for management of CAD we introduce this series of concise reviews that will focus on the contemporary management of these patients and investigate different approaches of their care.
Dr. Bernardo Cortese
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.
- Drug-coated balloon for the management of coronary chronic total occlusionsErick Sanchez-Jimenez, Rami El-Mokdad, Rima Chaddad, Bernardo CorteseRev. Cardiovasc. Med. 2022, 23(2), 42; https://doi.org/10.31083/j.rcm2302042143Download270Views
- DCBs as an adjuvant tool to DES for very complex coronary lesionsRima Chaddad, Rami El-Mokdad, Leontin Lazar, Bernardo CorteseRev. Cardiovasc. Med. 2022, 23(1), 13; https://doi.org/10.31083/j.rcm230101399Download292Views
- Is a high calcific burden an indication, or a contraindication for Drug Coated Balloon?Sandeep Basavarajaiah, Bhagya Harindi Loku Waduge, Richard Watkin, Sampath AthukoralaRev. Cardiovasc. Med. 2021, 22(4), 1087–1093; https://doi.org/10.31083/j.rcm220412098Download213Views
- Should paclitaxel be considered an old generation DCB? The limus eraGaetano di Palma, Erick Francisco Sanchez-Jimenez, Leontin Lazar, Bernardo CorteseRev. Cardiovasc. Med. 2021, 22(4), 1323–1330; https://doi.org/10.31083/j.rcm2204138109Download195Views
- Back to the future: the role of DCB for the treatment of coronary bifurcationAndrea Buono, Diego Maffeo, Mariano Pellicano, Giuseppe De Blasio, ... Alfonso IelasiRev. Cardiovasc. Med. 2021, 22(4), 1421–1428; https://doi.org/10.31083/j.rcm2204147129Download203Views
- Progress on developing an effective below-the-knee drug-coated balloonRym El Khoury, Marianne Brodmann, Peter A. SchneiderRev. Cardiovasc. Med. 2021, 22(3), 585–595; https://doi.org/10.31083/j.rcm2203070131Download1Citations278Views